Integer Holdings (ITGR) Earnings Date & Reports

Key Takeaways

• Integer Holdings is expected to report its third-quarter 2026 results on Thursday, October 22, in what is widely viewed as its final public earnings report before going private.
• Wall Street consensus points to adjusted earnings per share (EPS) of $1.69 on revenue of roughly $457.8 million for the quarter.
• Consensus implies a year-over-year revenue decline of about 2.1% and an adjusted EPS decline of roughly 5.6% versus the prior-year period.
• Sequentially, revenue is forecast to slip about 1% from the second quarter's $464 million, while EPS is expected to rise modestly.
• Because of the pending acquisition, the company has withdrawn its full-year guidance and is not expected to host an earnings conference call.
• Stockholders approved the KKR merger agreement on October 21, and shares are trading near $126.70, just below the $127 per-share deal price.

Earnings Context and Why It Matters

Integer Holdings Corporation is one of the world's largest medical device outsource manufacturers, serving the cardio and vascular, cardiac rhythm management, and neuromodulation markets as a contract development and manufacturing organization (CDMO). This report carries unusual weight because it is likely the company's last quarterly update as a public entity. In August, an affiliate of KKR-managed funds agreed to acquire Integer for $127 per share in cash, an enterprise value of about $5.7 billion. With the deal expected to close by the end of 2026, investors are reading the quarter less for standalone momentum and more as a final check on whether the business remains stable ahead of the ownership transition.

Earnings Expectations

Analysts expect Integer to report adjusted EPS of $1.69 on revenue of about $457.83 million for the third quarter ended in September. That forecast represents a sequential increase in profit but a modest decline in sales from the second quarter's $464 million. On a year-over-year basis, revenue is projected to fall about 2.1%, while adjusted EPS is expected to decline roughly 5.6%.

Estimates have been unusually stable, with EPS projections showing little change over the past week and the past two months, which suggests analysts see limited risk to the current outlook. Investors will also be watching margins closely. Integer posted a trailing twelve-month gross profit margin near 26.13%, and any sequential improvement would reinforce confidence in earnings quality even as revenue softens.

For context, in the second quarter of 2026 Integer beat expectations with adjusted EPS of $1.60 versus a consensus of about $1.51, while revenue of $464 million came in slightly ahead of forecasts. Those results offered some reassurance that the business remained steady ahead of the ownership change, though the company withdrew its financial outlook and canceled its earnings call following the buyout announcement.

AI Screener

For investors looking to monitor events like Integer's earnings report across the broader medical device and healthcare landscape, Tickeron's AI Screener offers a practical way to filter the market. This AI-powered stock and exchange-traded fund (ETF) discovery tool helps traders and investors sort through thousands of securities using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By scanning for technical patterns, fundamentals, trends, volatility, and AI-driven signals, the AI Screener can surface trade ideas, trending stocks, and breakout candidates far more efficiently than manual screening. Explore the AI Screener to refine your watchlist and identify opportunities as earnings season unfolds.

Market Reaction and Investor Sentiment

Heading into the report, sentiment is dominated by the pending transaction rather than by operating fundamentals. Shares are trading near $126.70, essentially in line with the $127 per-share cash consideration, and just below the 52-week high of $126.83. Nine analysts rate the stock a hold, with a consensus price target of about $121.80, which is roughly 4% below the current share price and well under the deal price. That muted target reflects expectations that the KKR acquisition will close rather than any projection of standalone performance.

Because the merger price effectively caps the upside, ordinary earnings-driven volatility is limited. The primary remaining risks are deal-related rather than financial: the company has disclosed several stockholder lawsuits and demand letters challenging the merger proxy. Investors will therefore read any commentary on the acquisition timeline, closing conditions, or regulatory status more closely than the headline numbers themselves.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important catalyst is the closing of the KKR transaction, which is anticipated by the end of 2026 now that stockholders have voted in favor of the merger and the required antitrust waiting period has been resolved. With the $127 per-share cash price acting as the effective ceiling for the stock, the remaining variables are largely procedural: the satisfaction of closing conditions and the resolution of outstanding litigation.

From an operating standpoint, investors should watch whether Integer's core cardiac and vascular franchises can hold momentum during the transition. Sequential revenue is forecast to decline about 1%, and any commentary on demand trends in electrophysiology and neuromodulation will help clarify whether previously disclosed product-related headwinds are stabilizing.

Margin trajectory also remains a focal point. The expectation that EPS will rise sequentially despite lower revenue suggests management's efficiency initiatives and product-mix shifts are supporting profitability. A gross margin reading consistent with or better than the trailing twelve-month level near 26% would reinforce that view.

Finally, because Integer has withdrawn full-year guidance and is not expected to hold a conference call, formal forward commentary may be limited. Absent an earnings call, the press release itself and any regulatory updates on the merger will likely carry most of the information investors need to assess the company's final chapter as a public entity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations